ES8602818A1 - Una composicion farmaceutica - Google Patents

Una composicion farmaceutica

Info

Publication number
ES8602818A1
ES8602818A1 ES537162A ES537162A ES8602818A1 ES 8602818 A1 ES8602818 A1 ES 8602818A1 ES 537162 A ES537162 A ES 537162A ES 537162 A ES537162 A ES 537162A ES 8602818 A1 ES8602818 A1 ES 8602818A1
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
alkoxy
independently
substituted phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES537162A
Other languages
English (en)
Other versions
ES537162A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of ES537162A0 publication Critical patent/ES537162A0/es
Publication of ES8602818A1 publication Critical patent/ES8602818A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PROCEDIMIENTO DE PREPARACION DE DERIVADOS FENOTIAZINICOS. CONSISTENTE EN CICLAR EN PRESENCIA DE UNA BASE Y UN DISOLVENTE INERTE EL COMPUESTO OBTENIDO AL CONDENSAR UNA DIHALOPIRAZINA DE FORMULA (III), DONDE X ES UN HALOGENO, CON UN AMINOBENCENOTIOL DE FORMULA (IV) DONDE U ES HS, OH O NHCN PARA PRODUCIR UN COMPUESTO DE FORMULA (I) DONDE R1-5 Y T SE ELIGEN ENTRE MULTIPLES SUSTITUYENTES, SIENDO Z O, NCN, S, SO O SO2. DE APLICACION EN EL TRATAMIENTO DE AFECCIONES ALERGICAS, ASMA, TRASTORNOS CARDIOVASCULARES EINFLAMACIONES, POR IMPEDIR ESTOS COMPUESTOS LA BIOSINTESIS DE LEUCOTRIENOS.
ES537162A 1983-10-31 1984-10-29 Una composicion farmaceutica Expired ES8602818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54716183A 1983-10-31 1983-10-31

Publications (2)

Publication Number Publication Date
ES537162A0 ES537162A0 (es) 1985-12-01
ES8602818A1 true ES8602818A1 (es) 1985-12-01

Family

ID=24183570

Family Applications (1)

Application Number Title Priority Date Filing Date
ES537162A Expired ES8602818A1 (es) 1983-10-31 1984-10-29 Una composicion farmaceutica

Country Status (6)

Country Link
EP (1) EP0140709B1 (es)
JP (1) JPS60115524A (es)
CA (1) CA1261834A (es)
DE (1) DE3484382D1 (es)
DK (1) DK516484A (es)
ES (1) ES8602818A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
HUT61980A (en) 1990-10-12 1993-03-29 Merck Frosst Canada Inc Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient
JPH0739423B2 (ja) * 1991-02-01 1995-05-01 ファイザー製薬株式会社 ピリミドベンゾチアジン誘導体を含む抗炎症剤
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
CZ168896A3 (en) * 1995-06-27 1997-01-15 Egyt Gyogyszervegyeszeti Gyar Oxaindene derivatives and process for preparing thereof
JP4028894B2 (ja) 1996-08-09 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾピペリジン誘導体
AU2641899A (en) 1998-02-27 1999-09-15 Eisai Co. Ltd. Heterocycle-fused benzothiazine derivatives
EP1231939A2 (en) * 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
DK516484D0 (da) 1984-10-30
JPS60115524A (ja) 1985-06-22
DK516484A (da) 1985-05-07
EP0140709B1 (en) 1991-04-03
DE3484382D1 (en) 1991-05-08
CA1261834A (en) 1989-09-26
EP0140709A3 (en) 1986-03-05
EP0140709A2 (en) 1985-05-08
ES537162A0 (es) 1985-12-01

Similar Documents

Publication Publication Date Title
ES8607256A1 (es) Un procedimiento para la preparacion de fenotiazonas halogenadas.
ES8602818A1 (es) Una composicion farmaceutica
BR9503582A (pt) Composto composiçao farmaceutica utilizaçao e método de tratamento de um ser humano
YU75590A (sh) 3-supstituisani-2-oksindol derivati i postupak za njihovo dobijanje
NO883587L (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolderivater.
HUP0401855A2 (hu) Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
CA2200707A1 (en) Novel prostaglandin synthase inhibitors
AU669032B2 (en) New indole, indazole and benzisoxazole compounds, process for preparing them and pharmaceutical compositions containing them
ATE135687T1 (de) Perhydroisoindolderivate, ihre herstellung und diese enthaltende arzneimittel
DE3762618D1 (de) Amidderivate.
HUP0103404A2 (hu) Oxazolidinonszármazékok, eljárás előállításukra, és az azokat tartalmazó gyógyászati készítmények
US6063807A (en) Cyclo-oxygenase inhibitor and amidine derivatives salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts
HUP9601176A2 (hu) Adhéziós receptor antagonista amidinszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
MXPA05012329A (es) Compuestos utiles para el tratamiento de enfermedades.
ES8707208A1 (es) Un procedimiento para la preparacion de derivados de benzo(a)fenotiazinas y benzo (a) fenoxazinas.
IL79841A0 (en) Heterocyclic compounds,their production and pharmaceutical compositions containing them
JPS59152366A (ja) 新規ニトロ脂肪族化合物、その製造法およびその用途
HUP0001910A2 (hu) Eljárás 4'-trifluormetil-bifenil-2-karbonsav-(1,2,3,4-tetrahidroizokinolin-6-il)- amid előállítására, és az eljáráshoz felhasználható köztitermékek
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE69323322T2 (de) Verwendung dimethylbenzofuran und dimethylbenzopyran derivate als 5-ht3 antagoniste
HUP0201357A2 (hu) Aszimmetrikus rézkomplex, előállítása, és eljárás ciklopropánkarbonsav-észter-származékok előállítására felhasználásával
DE69512208T2 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
JPH0959258A (ja) グアニジル誘導体
HUP0003475A2 (hu) Neutrofil-elasztáz gátló hatású pirrolo-pirrolon-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP9701921A2 (hu) Heterociklusos amino-metil-vegyületek, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények